Breast Cancer Therapeutics Market 2015 Breast Cancer Therapeutics Market | Page 2

therapeutics market based on various attributes such as company overview, financial overview, business
strategies, product portfolio, and recent developments. Major players profiled in this report include
AstraZeneca plc, Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc,
Novartis International AG, Pfizer, Inc., Puma Biotechnology, Sanofi S.A., and Teva Pharmaceutical
Industries Ltd.
To Get Full Detail of The Reports @ http://www.transparencymarketresearch.com/breast-cancer-
therapeutics-pipeline-analysis-market.html
Table Of Content
The global breast cancer therapeutics market has been segmented as follows:
Global Breast Cancer Therapeutics Market, by Drug Class
 Overview
 Global HER2 Inhibitors Market Revenue, 2015–2023 (US$ Mn)
 Herceptin (Trastuzumab)
 Tykerb (Lapatinib)
 Perjeta (Pertuzumab)
 Kadcyla (Ado-trastuzumab emtansine)
 Global Mitotic Inhibitors Market Revenue, 2015–2023 (US$ Mn)
 Halaven (Eribulin)
 Taxotere (Docetaxel)
 Ixempra (Ixabepilone)
 Global Anti-metabolites Market Revenue, 2015–2023 (US$ Mn)
 Gemzar (Gemcitabine)
 Global Aromatase Inhibitors Market Revenue, 2015–2023 (US$ Mn)
o Femara (Leterozole)
o Aromasin (Exemestane)
o Arimidex (Anastrozole)
o Ibrance (Palbociclib)
o Afinitor (Everolimus)
 Global Hormone Receptor Market Revenue, 2015–2023 (US$ Mn)
 Zoladex
 Faslodex
 Fareston
Global Breast Cancer Therapeutics Market, by Geography
 North America
o U.S.
o Canada
 Europe
o Germany
o U.K.
 Asia Pacific
o Japan
o South Korea
o Rest of Asia Pacific